Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and imatinib in early chronic phase CML
NCT00769327Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Feb 2009
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib, imatinib in Chronic Myeloid Leukemia (CML), sponsored by GIMEMA. Started Feb 2009; status: completed.
02
Drugs
nilotinibimatinib
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT00769327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00769327.